Education
About Us
Working with TipRanks
Follow Us
Fennec Pharmaceuticals (TSE:FRX)
TSX:FRX
FRX Stock Chart & Stats
C$10.16
C$0.03(0.34%)
At close: 4:00 PM EST
C$10.16
C$0.03(0.34%)
Day’s Range― - ―
52-Week RangeC$7.02 - C$13.83
Previous CloseN/A
Volume1.30K
Average Volume (3M)686.00
Market Cap
C$346.86M
Enterprise ValueC$356.93M
Total Cash (Recent Filing)C$21.93M
Total Debt (Recent Filing)C$18.09M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Apr 01, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding34,139,973
10 Day Avg. Volume43
30 Day Avg. Volume686
Financial Highlights & Ratios
PEG Ratio3.19
Price to Book (P/B)-22.88
Price to Sales (P/S)2.83
P/FCF Ratio4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$20.42Price Target Upside100.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet And Financial FlexibilityRedemption of all outstanding debt and a strengthened balance sheet improves financial flexibility to fund commercial expansion and sustain operating margins.
Guideline Inclusion And Market AccessInclusion of PEDMARK in national clinical guidelines for adolescents and young adults broadens the eligible patient population and supports expanded prescribing by oncologists.
Regulatory DifferentiationFDA approval as the only therapy indicated to reduce cisplatin-associated hearing loss creates a differentiated product profile that could drive adoption in oncology treatment protocols.
Bears Say
Commercial Adoption RiskUncertain commercial adoption of PEDMARK among clinicians and payers could slow revenue growth despite clinical benefits.
Intellectual Property RiskPotential challenges to intellectual property protection could erode exclusivity and invite competitive entrants that pressure prices and market share.
Fennec Pharmaceuticals News
FRX FAQ
What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was C$7.02 and its highest was C$13.83 in the past 12 months.
What is Fennec Pharmaceuticals’s market cap?
Fennec Pharmaceuticals’s market cap is C$346.86M.
When is Fennec Pharmaceuticals’s upcoming earnings report date?
Fennec Pharmaceuticals’s upcoming earnings report date is Apr 01, 2026 which is in 80 days.
How were Fennec Pharmaceuticals’s earnings last quarter?
Fennec Pharmaceuticals released its earnings results on Nov 13, 2025. The company reported -C$0.028 earnings per share for the quarter, beating the consensus estimate of -C$0.031 by C$0.003.
Is Fennec Pharmaceuticals overvalued?
According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
Does Fennec Pharmaceuticals pay dividends?
Fennec Pharmaceuticals does not currently pay dividends.
What is Fennec Pharmaceuticals’s EPS estimate?
Fennec Pharmaceuticals’s EPS estimate is 0.05.
How many shares outstanding does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals has 34,139,973 shares outstanding.
What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
Fennec Pharmaceuticals reported an EPS of -C$0.028 in its last earnings report, beating expectations of -C$0.031. Following the earnings report the stock price went down -1.109%.
Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:FRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fennec Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$20.42 (100.95% Upside)
C$20.42 (100.95% Upside)
Blogger Sentiment
Bullish
TSE:FRX Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $9.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
28.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-16.39%
Trailing 12-Months
Company Description
Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
FRX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong revenue growth and market adoption for PEDMARK, supported by strategic expansions and new accounts. However, increased operating expenses and dependency on market expansion present challenges. The momentum in PEDMARK's adoption and international expansion efforts suggest positive future prospects.View all TSE:FRX earnings summariesFRX Stock 12 Month Forecast
Average Price Target
C$20.42
▲(100.95% Upside)
Technical Analysis
Satellos Bioscience
―
Helix BioPharma
―
NervGen Pharma
―
Eupraxia Pharmaceuticals
―
ME Therapeutics Holdings, Inc.
―
Options Prices
Currently, No data available
---